AMGN up +1.39% percent Today $AMGN High is at 159.93 and the Low 156.66 with current volume of 542,492.
Recent News posted below.
Amgen Inc AMGN other info.
http://investorshangout.com/Amgen-Inc-AMGN-53303/
AMGN Amgen Inc Recent Headline News
Early Glance: Biotechnology companies
AP - 24 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 100.86 (-1.20), AMGN: 159.36 (+1.68), CELG: 105.03 (+0.98)
Global Biologic Therapeutics Market 2014-2018: Key Vendors are Amgen, F. Hoffmann-La Roche, Novo Nordisk and Sanofi
M2 - Mon Nov 17, 3:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/tx4gv7/global_biologic) has announced the addition of the "Global Biologic Therapeutics Market 2014-2018" report to their offering. One key trend upcoming in this market is the emergence of targeted therapies, which are generally associated with better efficacy and safety compared to traditional drugs. Thus, these drugs are expected to increase patient compliance and fuel the market. According to the report, an aging population is one of the major drivers of the market. An increase in the aging population is expected to increase the population of patients suffering from a variety of diseases, and thereby drive the market. Further, the report states that the need for cold storage is one of the major challenges in the market. Cold storage increases the transportation and storage costs of the therapeutic products, thereby adding to the final cost of the products. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Molecule Type 08. Geographical Segmentation 09. Buying Criteria 10. Global Protein Therapeutics Market 11. Global Vaccines Market 12. Global Cell Therapy Market 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Competitive Scenario 20. Market Share Analysis 2013 21. Market Assessment of Major Biologic Therapeutics of Key Vendors 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Abbvie - Amgen - AstraZeneca - Bavarian Nordic - Baxter International - Beijing Minhai Biotechnology - Bharat Biotech - Bharat Immunologicals and Biologicals - Bio Med - Biodel - Bristol-Myers Squibb - DiaVacs - Diamyd Medical - Dynavax Technologies - Eli Lilly - F. Hoffmann-La Roche - Generex Biotechnology - Hualan Biological Engineering - Imunoloski Zavod - Indian Immunologicals - JN International Medical - Janssen Pharmaceuticals - Sanofi - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Tolerion - Vacunas Finlay - XOMA - Zydus Cadila - bioCSL For more information visit http://www.researchandmarkets.com/research/tx...l_biologic
DVAX: 14.32 (-0.36), BAX: 71.66 (-0.09), AMGN: 159.36 (+1.68), LLY: 67.22 (-0.11), BMY: 58.22 (+0.27), SVA: 4.76 (-0.49)
Final Glance: Biotechnology companies
AP - Fri Nov 14, 5:03PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 100.86 (-1.20), AMGN: 159.36 (+1.68), CELG: 105.03 (+0.98)
Amgen Set to Possibly Rebound After Yesterday's Selloff of 1.97%
Comtex SmarTrend(R) - Fri Nov 14, 3:45PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $156.62 to a high of $161.28. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $159.58 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 159.36 (+1.68)
After Yesterday's Decline of 1.97%, Amgen Offers Investors Better Value
Comtex SmarTrend(R) - Fri Nov 14, 3:44PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $156.62 to a high of $161.28. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $159.58 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 159.36 (+1.68)
Amgen To Present At The Jefferies Global Healthcare Conference
PR Newswire - Fri Nov 14, 3:15PM CST
Amgen (NASDAQ: AMGN) will participate at the Jefferies Global Healthcare Conference on Wednesday, Nov. 19, 2014, in London, beginning at 8:40 a.m. GMT. Arvind Sood, vice president of Investor Relations at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.
AMGN: 159.36 (+1.68)
Midday Glance: Biotechnology companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 100.86 (-1.20), AMGN: 159.36 (+1.68), CELG: 105.03 (+0.98)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 306.86 (+1.43), VRTX: 111.76 (+0.42), GILD: 100.86 (-1.20), ALXN: 189.93 (+1.17), AMGN: 159.36 (+1.68), IBB: 291.07 (+2.90), REGN: 405.93 (+10.73), CELG: 105.03 (+0.98)
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
Alexander J. Poulos - Seeking Alpha - Fri Nov 14, 8:23AM CST
It is not often for one to come across such an explosive growth company such as Gilead Sciences (NASDAQ: GILD ). By virtue of its stronghold on the Hepatitis C market (HCV) combined with its dominant share in the HIV market, GILD has many...
GILD: 100.86 (-1.20), AMGN: 159.36 (+1.68), SNY: 47.34 (+0.66), REGN: 405.93 (+10.73)
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:10PM CST
AstraZeneca (AZN) and Amgen (AMGN) announced encouraging results from a phase III study on brodalumab.
JNJ: 108.37 (+0.21), AZN: 72.43 (-0.42), AMGN: 159.36 (+1.68), AMAG: 34.63 (+0.63)
ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination
Lance Brofman - at Seeking Alpha - Thu Nov 13, 8:52AM CST
OREX: 5.61 (-0.04), HLF: 38.49 (-0.01), NVO: 43.77 (-0.36), VVUS: 3.15 (-0.10), AMGN: 159.36 (+1.68), GSK: 45.96 (+0.22), ARNA: 4.57 (+0.04)
Critical Alerts For Caesars Entertainment, Orexigen Therapeutics, Amazon.com, Toyota Motor and Amgen Released By InvestorsObserver
PR Newswire - Thu Nov 13, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for CZR, OREX, AMZN, TM and AMGN.
AMZN: 321.70 (-6.12), OREX: 5.61 (-0.04), AMGN: 159.36 (+1.68), TM: 118.96 (-0.86), CZR: 15.87 (-0.63)
Biothera Names Carey Anderson VP of Regulatory Affairs
Business Wire - Thu Nov 13, 8:30AM CST
Carey Anderson has joined Biothera as Vice President of Regulatory Affairs for its Pharmaceutical business.
MACK: 8.72 (+0.24), AMGN: 159.36 (+1.68)
The Zacks Analyst Blog Highlights: Dendreon, Amgen, Regeneron, AbbVie and Gilead
PR Newswire - Thu Nov 13, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Dendreon (Nasdaq
NDN-Free Report), Amgen (Nasdaq:AMGN-Free Report), Regeneron (Nasdaq:REGN-Free Report), AbbVie (NYSE:ABBV-Free Report) and Gilead (Nasdaq:GILD-Free Report).
AMGN: 159.36 (+1.68)
Acute Coronary Syndrome: Global Drug Forecast and Market Analysis to 2023 - Market to Triple from $12.3 Billion in 2013 to $43.4 Billion by 2023
M2 - Thu Nov 13, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/mhkp4w/pharmapoint) has announced the addition of the "PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023" report to their offering. New Blockbuster Drugs to More than Triple Acute Coronary Syndrome Treatment Market Value by 2023 The launch of several drugs with extraordinary blockbuster potential will cause the acute coronary syndrome (ACS) treatment market to more than triple in value, from $12.3 billion in 2013 to $43.4 billion by 2023 This report states that across seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan) there are three monoclonal antibodies (mAbs), all PCSK9 inhibitors, with the potential to reshape the post-ACS, dyslipidemia landscape. Amgen's evolocumab, Sanofi and Regeneron's alirocumab, and Pfizer's bococizumab are all demonstrating safe and significant reductions of serum LDL-C levels in major clinical trials, and The authors expects these treatments to be launched in the middle of the forecast period. Eric J. Dimise, Ph.D., The authors's Analyst covering Cardiovascular and Metabolic Disorders, says: These three mAbs, which fulfill a critical unmet need by offering novel approaches to LDL-C reduction for patients who cannot tolerate statins, are likely to be prescribed long-term, marking the first time that biologics will enter the mainstream of chronic ACS treatment. The premium price of PCSK9 mAbs means that they will be able to achieve substantial sales with a relatively small patient population. We forecast that they will account for around 40% of ACS sales by 2023, with a global value that slightly exceeds $17.5 billion. The authors has also identified two new anticoagulants, Janssen's Xarelto and Merck's Zontivity, which are both on track to compete directly with warfarin and post impressive sales over the next nine years. Dimise states: Xarelto is anticipated to achieve approval for the ACS indication in the US by 2018. When added to the drug's mounting sales in the EU, this will result in peak-year sales approaching $8 billion for ACS alone. Meanwhile, the PAR1 inhibitor, Zontivity, which enters the US market in Q3 of 2014, could achieve worldwide sales exceeding $1 billion by 2015. The dramatic increase in overall ACS market value is attributable to the launch of these and several other drugs currently in the late-stage development pipeline, all of which have extraordinary blockbuster potential, concludes the analyst. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Unmet Need and Opportunity 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Amgen - AstraZeneca - Bristol-Myers Squibb - Daiichi Sankyo - Eli Lilly - GlaxoSmithKline - Janssen Pharmaceuticals (Johnson & Johnson) - The Medicines Company - Merck & Co. - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/mh...harmapoint
JNJ: 108.39 (+0.23), MRK: 59.80 (+0.73), AMGN: 159.36 (+1.68), LLY: 67.22 (-0.11), GSK: 45.96 (+0.22), BMY: 58.22 (+0.27)
Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions
PR Newswire - Wed Nov 12, 3:35PM CST
Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the American Heart Association (AHA) Scientific Sessions 2014 on Tuesday, Nov. 18, at 6 p.m. CT. Rob Scott, M.D., vice president of Global Development at Amgen, and Scott Wasserman, M.D., executive medical director of Global Development at Amgen, along with clinical investigators, will participate in this call to discuss Amgen's cardiovascular program, including the evolocumab data presented at the congress.
AMGN: 159.36 (+1.68)
Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab
PR Newswire - Wed Nov 12, 3:01PM CST
Amgen (NASDAQ:AMGN) today announced that it will present 13 abstracts at the upcoming American Heart Association (AHA) Scientific Sessions 2014 being held Nov. 15-19 in Chicago, including data from studies evaluating evolocumab, an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood.1
AMGN: 159.36 (+1.68)
Recent News posted below.
Amgen Inc AMGN other info.
http://investorshangout.com/Amgen-Inc-AMGN-53303/
AMGN Amgen Inc Recent Headline News
Early Glance: Biotechnology companies
AP - 24 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 100.86 (-1.20), AMGN: 159.36 (+1.68), CELG: 105.03 (+0.98)
Global Biologic Therapeutics Market 2014-2018: Key Vendors are Amgen, F. Hoffmann-La Roche, Novo Nordisk and Sanofi
M2 - Mon Nov 17, 3:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/tx4gv7/global_biologic) has announced the addition of the "Global Biologic Therapeutics Market 2014-2018" report to their offering. One key trend upcoming in this market is the emergence of targeted therapies, which are generally associated with better efficacy and safety compared to traditional drugs. Thus, these drugs are expected to increase patient compliance and fuel the market. According to the report, an aging population is one of the major drivers of the market. An increase in the aging population is expected to increase the population of patients suffering from a variety of diseases, and thereby drive the market. Further, the report states that the need for cold storage is one of the major challenges in the market. Cold storage increases the transportation and storage costs of the therapeutic products, thereby adding to the final cost of the products. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Molecule Type 08. Geographical Segmentation 09. Buying Criteria 10. Global Protein Therapeutics Market 11. Global Vaccines Market 12. Global Cell Therapy Market 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Competitive Scenario 20. Market Share Analysis 2013 21. Market Assessment of Major Biologic Therapeutics of Key Vendors 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Abbvie - Amgen - AstraZeneca - Bavarian Nordic - Baxter International - Beijing Minhai Biotechnology - Bharat Biotech - Bharat Immunologicals and Biologicals - Bio Med - Biodel - Bristol-Myers Squibb - DiaVacs - Diamyd Medical - Dynavax Technologies - Eli Lilly - F. Hoffmann-La Roche - Generex Biotechnology - Hualan Biological Engineering - Imunoloski Zavod - Indian Immunologicals - JN International Medical - Janssen Pharmaceuticals - Sanofi - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Tolerion - Vacunas Finlay - XOMA - Zydus Cadila - bioCSL For more information visit http://www.researchandmarkets.com/research/tx...l_biologic
DVAX: 14.32 (-0.36), BAX: 71.66 (-0.09), AMGN: 159.36 (+1.68), LLY: 67.22 (-0.11), BMY: 58.22 (+0.27), SVA: 4.76 (-0.49)
Final Glance: Biotechnology companies
AP - Fri Nov 14, 5:03PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 100.86 (-1.20), AMGN: 159.36 (+1.68), CELG: 105.03 (+0.98)
Amgen Set to Possibly Rebound After Yesterday's Selloff of 1.97%
Comtex SmarTrend(R) - Fri Nov 14, 3:45PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $156.62 to a high of $161.28. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $159.58 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 159.36 (+1.68)
After Yesterday's Decline of 1.97%, Amgen Offers Investors Better Value
Comtex SmarTrend(R) - Fri Nov 14, 3:44PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $156.62 to a high of $161.28. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $159.58 on volume of 4.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 159.36 (+1.68)
Amgen To Present At The Jefferies Global Healthcare Conference
PR Newswire - Fri Nov 14, 3:15PM CST
Amgen (NASDAQ: AMGN) will participate at the Jefferies Global Healthcare Conference on Wednesday, Nov. 19, 2014, in London, beginning at 8:40 a.m. GMT. Arvind Sood, vice president of Investor Relations at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.
AMGN: 159.36 (+1.68)
Midday Glance: Biotechnology companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 100.86 (-1.20), AMGN: 159.36 (+1.68), CELG: 105.03 (+0.98)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 306.86 (+1.43), VRTX: 111.76 (+0.42), GILD: 100.86 (-1.20), ALXN: 189.93 (+1.17), AMGN: 159.36 (+1.68), IBB: 291.07 (+2.90), REGN: 405.93 (+10.73), CELG: 105.03 (+0.98)
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
Alexander J. Poulos - Seeking Alpha - Fri Nov 14, 8:23AM CST
It is not often for one to come across such an explosive growth company such as Gilead Sciences (NASDAQ: GILD ). By virtue of its stronghold on the Hepatitis C market (HCV) combined with its dominant share in the HIV market, GILD has many...
GILD: 100.86 (-1.20), AMGN: 159.36 (+1.68), SNY: 47.34 (+0.66), REGN: 405.93 (+10.73)
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:10PM CST
AstraZeneca (AZN) and Amgen (AMGN) announced encouraging results from a phase III study on brodalumab.
JNJ: 108.37 (+0.21), AZN: 72.43 (-0.42), AMGN: 159.36 (+1.68), AMAG: 34.63 (+0.63)
ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination
Lance Brofman - at Seeking Alpha - Thu Nov 13, 8:52AM CST
OREX: 5.61 (-0.04), HLF: 38.49 (-0.01), NVO: 43.77 (-0.36), VVUS: 3.15 (-0.10), AMGN: 159.36 (+1.68), GSK: 45.96 (+0.22), ARNA: 4.57 (+0.04)
Critical Alerts For Caesars Entertainment, Orexigen Therapeutics, Amazon.com, Toyota Motor and Amgen Released By InvestorsObserver
PR Newswire - Thu Nov 13, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for CZR, OREX, AMZN, TM and AMGN.
AMZN: 321.70 (-6.12), OREX: 5.61 (-0.04), AMGN: 159.36 (+1.68), TM: 118.96 (-0.86), CZR: 15.87 (-0.63)
Biothera Names Carey Anderson VP of Regulatory Affairs
Business Wire - Thu Nov 13, 8:30AM CST
Carey Anderson has joined Biothera as Vice President of Regulatory Affairs for its Pharmaceutical business.
MACK: 8.72 (+0.24), AMGN: 159.36 (+1.68)
The Zacks Analyst Blog Highlights: Dendreon, Amgen, Regeneron, AbbVie and Gilead
PR Newswire - Thu Nov 13, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Dendreon (Nasdaq
NDN-Free Report), Amgen (Nasdaq:AMGN-Free Report), Regeneron (Nasdaq:REGN-Free Report), AbbVie (NYSE:ABBV-Free Report) and Gilead (Nasdaq:GILD-Free Report). AMGN: 159.36 (+1.68)
Acute Coronary Syndrome: Global Drug Forecast and Market Analysis to 2023 - Market to Triple from $12.3 Billion in 2013 to $43.4 Billion by 2023
M2 - Thu Nov 13, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/mhkp4w/pharmapoint) has announced the addition of the "PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023" report to their offering. New Blockbuster Drugs to More than Triple Acute Coronary Syndrome Treatment Market Value by 2023 The launch of several drugs with extraordinary blockbuster potential will cause the acute coronary syndrome (ACS) treatment market to more than triple in value, from $12.3 billion in 2013 to $43.4 billion by 2023 This report states that across seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan) there are three monoclonal antibodies (mAbs), all PCSK9 inhibitors, with the potential to reshape the post-ACS, dyslipidemia landscape. Amgen's evolocumab, Sanofi and Regeneron's alirocumab, and Pfizer's bococizumab are all demonstrating safe and significant reductions of serum LDL-C levels in major clinical trials, and The authors expects these treatments to be launched in the middle of the forecast period. Eric J. Dimise, Ph.D., The authors's Analyst covering Cardiovascular and Metabolic Disorders, says: These three mAbs, which fulfill a critical unmet need by offering novel approaches to LDL-C reduction for patients who cannot tolerate statins, are likely to be prescribed long-term, marking the first time that biologics will enter the mainstream of chronic ACS treatment. The premium price of PCSK9 mAbs means that they will be able to achieve substantial sales with a relatively small patient population. We forecast that they will account for around 40% of ACS sales by 2023, with a global value that slightly exceeds $17.5 billion. The authors has also identified two new anticoagulants, Janssen's Xarelto and Merck's Zontivity, which are both on track to compete directly with warfarin and post impressive sales over the next nine years. Dimise states: Xarelto is anticipated to achieve approval for the ACS indication in the US by 2018. When added to the drug's mounting sales in the EU, this will result in peak-year sales approaching $8 billion for ACS alone. Meanwhile, the PAR1 inhibitor, Zontivity, which enters the US market in Q3 of 2014, could achieve worldwide sales exceeding $1 billion by 2015. The dramatic increase in overall ACS market value is attributable to the launch of these and several other drugs currently in the late-stage development pipeline, all of which have extraordinary blockbuster potential, concludes the analyst. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Unmet Need and Opportunity 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Amgen - AstraZeneca - Bristol-Myers Squibb - Daiichi Sankyo - Eli Lilly - GlaxoSmithKline - Janssen Pharmaceuticals (Johnson & Johnson) - The Medicines Company - Merck & Co. - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/mh...harmapoint
JNJ: 108.39 (+0.23), MRK: 59.80 (+0.73), AMGN: 159.36 (+1.68), LLY: 67.22 (-0.11), GSK: 45.96 (+0.22), BMY: 58.22 (+0.27)
Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions
PR Newswire - Wed Nov 12, 3:35PM CST
Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the American Heart Association (AHA) Scientific Sessions 2014 on Tuesday, Nov. 18, at 6 p.m. CT. Rob Scott, M.D., vice president of Global Development at Amgen, and Scott Wasserman, M.D., executive medical director of Global Development at Amgen, along with clinical investigators, will participate in this call to discuss Amgen's cardiovascular program, including the evolocumab data presented at the congress.
AMGN: 159.36 (+1.68)
Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab
PR Newswire - Wed Nov 12, 3:01PM CST
Amgen (NASDAQ:AMGN) today announced that it will present 13 abstracts at the upcoming American Heart Association (AHA) Scientific Sessions 2014 being held Nov. 15-19 in Chicago, including data from studies evaluating evolocumab, an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood.1
AMGN: 159.36 (+1.68)
